ReviewFrontiers in pharmacology2022
Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial.Schizophrenia bulletin · 2025Trial
- Efficacy of spironolactone as adjunctive therapy to sodium valproate in bipolar-I disorder: A double-blind, randomized, placebo-controlled clinical trial.Brain and behavior · 2023Trial
- Antidepressant Mechanisms of L-Theanine in Tea Based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations.Foods (Basel, Switzerland) · 2026Article
- Chemotherapy-Induced Remodeling of the Gut Microbiota-Inflammation Axis: Implications for the Course of Bipolar Disorder.Journal of multidisciplinary healthcare · 2026Review
- Can bacteria control the human brain?Communicative & integrative biology · 2026Review
- Association between choroid plexus volume and cognitive function in older-age bipolar disorder.BMC psychiatry · 2025Article
- Role of the gut-brain axis in neurological diseases: Molecular connections and therapeutic implications (Review).International journal of molecular medicine · 2025Review
- The Microbiota-Gut-Brain Connection: A New Horizon in Neurological and Neuropsychiatric Disorders.CNS neuroscience & therapeutics · 2025Review
- A Cross-Sectional Comparative Study: Could Asprosin and Peptide Tyrosine-Tyrosine Be Used in Schizophrenia to Define the Disease and Determine Its Phases?Diagnostics (Basel, Switzerland) · 2025Article
- Gut Microbiota and Mental Health: A Comprehensive Review of Gut-Brain Interactions in Mood Disorders.Cureus · 2025Review
- Serum Asprosin and Peptide Tyrosine Tyrosine (PYY) Levels in Bipolar Disorder.Journal of clinical medicine · 2025Article
- Genes of cancer-related fatigue: a scoping review.Frontiers in oncology · 2024Article
- The gut microbiota-brain connection: insights into major depressive disorder and bipolar disorder.Frontiers in psychiatry · 2024Review
- Roles of Omega-3 Polyunsaturated Fatty Acids in Managing Cognitive Impairment in Chronic Obstructive Pulmonary Disease: A Review.Nutrients · 2023Review
- Arketamine for cognitive impairment in psychiatric disorders.European archives of psychiatry and clinical neuroscience · 2023Review
- Characterization of gut microbiota profile in Iranian patients with bipolar disorder compared to healthy controls.Frontiers in cellular and infection microbiology · 2023Article
- The Microbiota-Gut-Brain Axis in Psychiatric Disorders.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have reported that the gut microbiota influences mood and cognitive function through the gut-brain axis, which is involved in the pathophysiology of neurocognitive and mental disorders, including Parkinson's disease, Alzheimer's disease, and schizophrenia. These disorders have similar pathophysiology to that of cognitive dysfunction in bipolar disorder (BD), including neuroinflammation and dysregulation of various neurotransmitters (i.e., serotonin and dopamine). There is also emerging evidence of alterations in the gut microbial composition of patients with BD, suggesting that gut microbial dysbiosis contributes to disease progression and cognitive impairment in BD. Therefore, microbiota-centered treatment might be an effective adjuvant therapy for BD-related cognitive impairment. Given that studies focusing on connections between the gut microbiota and BD-related cognitive impairment are lagging behind those on other neurocognitive disorders, this review sought to explore the potential mechanisms of how gut microbial dysbiosis affects cognitive function in BD and identify potential microbiota-centered treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.